N-Nitroso-N-methylurea (NMU) is a nitrosamine compound widely employed as a potent mutagen in biomedical research, as a synthetic intermediate in pharmaceutical manufacturing, and in niche agro‑chemical applications. The N-Nitroso-N-methylurea market size was estimated at approximately USD 45 million in 2025, and industry analysts project a CAGR of 6.2% through the 2026‑2033 market forecast, driven by expanding oncology research pipelines, heightened demand for high‑purity intermediates, and stricter regulatory scrutiny of nitrosamine residues. Key forces shaping the market include rapid technology shifts toward greener synthesis routes, evolving regulatory frameworks that mandate impurity control, and supply‑chain dynamics as raw‑material sourcing tightens. North America remains the largest region, anchored by robust pharmaceutical R&D, while the Asia‑Pacific is emerging as the fastest‑growing market due to accelerating biotech investments in China, India, and Japan.